ArticleMolecular biology reports2025
Fisetin mitigates cisplatin-induced peripheral neuropathy: a behavioral and immunohistochemical study.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of oxidative stress and antioxidant therapy in cisplatin neurotoxicity: preclinical evidence in the last decade.Archives of toxicology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCisplatin (CIS), a commonly used chemotherapeutic drug, often causes peripheral neuropathy, considerably affecting patients' quality of life. The present study investigated the neuroprotective effects of fisetin, a natural flavonoid with antioxidant and anti-inflammatory features, in a rat model of cisplatin-induced peripheral neuropathy. METHODS AND
resultsMale Wistar rats were divided into six groups: sham, neuropathy (CIS, 3 mg/kg, 5 weeks), fisetin treatment (CIS + 10 mg/kg and CIS + 20 mg/kg), and drugs control groups (10 mg/kg and 20 mg/kg fisetin alone). Behavioural experiments were conducted to evaluate motor coordination and sensory function, electrophysiologically measured nerve conduction velocity (NCV). Gene expression studies were conducted for NF-kB and GPX4 to investigate oxidative stress and inflammation. Finally, confocal microscopy studies were used to evaluate the structure of the sciatic nerve. Cisplatin induced motor impairments, sensory dysfunction, mechanical allodynia, diminished nerve conduction velocity, myelin deterioration (decreased MBP), and increased neuroinflammation (elevated GFAP and NF-kB, decreased GPX4). Fisetin, specifically at a dose of 10 mg/kg, markedly enhanced motor coordination, sensory thresholds, NCV, maintained myelin integrity, reduced glial activation, and restored oxidative and inflammatory balance by elevating GPX4 levels and decreasing NF-kB expression.
conclusionsThese results highlight fisetin's potential as a therapeutic agent for cisplatin-induced neuropathy, emphasising its role in restoring molecular, structural, and functional integrity within the peripheral nervous system.
Indexed as
Identifiers
40167901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.